2025 Annual Meeting | C86 - Clinical Pearls in Autoimmune Neurology: Real-world Cases

Date Monday 04/07/25

Time 07:00 AM - 09:00 AM PDT Add To Calendar

Location San Diego Convention Center | 6A

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Sarosh R. Irani, MD, PhD, FRCP, FEAN

Topic(s) Autoimmune Neurology

Learning Objectives Participants should be able to recognize and become familiar with case-based descriptions of some of neurology's most treatable autoimmune conditions, spanning the breadth of demyelination, encephalitis and peripheral neuropathies; recall and interpret investigation features which lead to, and divert from, an accurate autoimmune diagnosis including conditions with antibodies against AQP4, MOG, GAD, LGI1, CASPR2, Iglon5, and NF-155; and formulate, appraise, and synthesise management plans for these patients

CME Available 2.00 CME credits

Core Competencies Interpersonal and Communication Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Intermediate

Recommended Audience Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:05 AM PDT	Introduction	Introduction Sarosh R. Irani, MD, PhD, FRCP, FEAN
07:05 AM - 07:40 AM PDT	Speaker	Pearls and Pitfalls in the Diagnosis of Demyelinating Syndromes Brian G. Weinshenker, MD, FAAN
07:40 AM - 08:15 AM PDT	Speaker	Under-recognition and Misdiagnosis in Autoimmune Encephalitis Sarosh R. Irani, MD, PhD, FRCP, FEAN
08:15 AM - 08:40 AM PDT	Speaker	Treatable Immunology from Nerve to Muscle Christopher Lamb, MD
08:40 AM - 09:00 AM PDT	Q&A	Questions and Answers Sarosh R. Irani, MD, PhD, FRCP, FEAN, Brian G. Weinshenker, MD, FAAN, Christopher Lamb, MD

Faculty Disclosures
Sarosh R. Irani, MD, PhD, FRCP, FEAN	Dr. Irani has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for UCB, Immunovant, MedImmun, Roche, Janssen, Cerebral therapeutics, Biogen, Amgen, Argenex, Clarivate, IQVIA, BioHaven therapeutics, ADC therapeutics, Brain, CSL Behring, and ONO Pharma.. Dr. Irani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Irani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Irani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Brain. Dr. Irani has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for LLPs. Dr. Irani has received intellectual property interests from a discovery or technology relating to health care. Dr. Irani has received intellectual property interests from a discovery or technology relating to health care. Dr. Irani has received intellectual property interests from a discovery or technology relating to health care.
Brian G. Weinshenker, MD, FAAN	Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CANbridge Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $0-$499 for serving as a Consultant for CALIBR. Dr. Weinshenker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Group (Chugai, Genentech, Roche). Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care.
Christopher Lamb, MD	Dr. Lamb has received research support from Immunovant, Inc.

��ɫ��

��ɫ��